A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
On 11 August, Lula and ministers unveiled a new Growth Acceleration Programme, according to the proposal, an estimated 1.7 trillion reais (worth around US$350 billion at the time) will be spent over the following 4 years. Of this, 610 billion is expected to be spent on slum urbanisation programmes, including the development of housing, public transport, sanitation, energy and protection from natural disasters, this includes further investments on social infrastructure programmes such as Minha Casa, Minha Vida, Luz Para Todos and Água Para Todos, as well as creation and expansion of ports, airports, motorways and railways. 540 billion is expected to be spent on expanding the electric grid and petrochemical industries, with 80% of the newly developed electric production capacity being expected to come from renewable sources; 349 billion is expected to be spent on transportation infrastructure, including for motor vehicles, trains, marine vehicles, and aeroplanes. Lula also announced the construction of the "West-East Integration Railway (FIOL)" as the first project of the programme, which will connect the southwest of Bahia to the coast of southern Bahia. Other areas of investment include "digital inclusion and connectivity" (expansion of 4G and 5G networks and digital education), healthcare (construction of new basic health units and maternities, as well purchase of ambulances and vaccines), education (construction, expansion and modernization of day care centers, full-time schools and federal institutes and universities) and defence infrastructure.
David Neal, the former Independent Chief Inspector of Borders and Immigration, has described the Home Office is dysfunctional and in urgent need of reform, citing problems with immigration as an example. 12 March – A spokesman for the prime minister describes the remarks allegedly made by Frank Hester about Diane Abbott as "racist and wrong". A recall petition opens in the Blackpool South constituency following Scott Benton's 35 day suspension from Parliament. 13 March – Sunak tells Prime Minister's Questions he will not return £10m donated to the Conservative Party by Frank Hester, because he has apologised and "his remorse should be accepted". The UK government announces a scheme to offer failed asylum seekers £3,000 if they agree to move to Rwanda voluntarily. The UK government announces a ban on foreign state ownership of British newspapers and news magazines following controversy over a potential purchase of The Telegraph by a consortium backed by the United Arab Emirates. Middlesbrough MP Andy McDonald regains the Labour whip. 14 March – Russia is reported to have jammed the GPS signal of an RAF plane carrying Defence Secretary Grant Shapps back to the UK from Poland the previous day for around 30 minutes as the plane flew near the border of the Russian territory of Kaliningrad. Speaking in the House of Commons, Secretary of State for Levelling Up, Housing and Communities Michael Gove outlines the UK government's new definition of extremism, and names five groups that would be assessed against the new criteria.
=== Physical properties === Plutonium, like most metals, has a bright silvery appearance at first, much like nickel, but it oxidizes very quickly to a dull gray, though yellow and olive green are also reported. At room temperature plutonium is in its α (alpha) form. This allotrope is about as hard and brittle as gray cast iron. When plutonium is alloyed with other metals, the high-temperature δ allotrope is stabilized at room temperature, making it soft and ductile. Unlike most metals, it is not a good conductor of heat or electricity. It has a low melting point (640 °C, 1,184 °F) and an unusually high boiling point (3,228 °C, 5,842 °F). This gives a large range of temperatures (over 2,500 kelvin wide) at which plutonium is liquid, but this range is neither the greatest among all actinides nor among all metals, with neptunium theorized to have the greatest range in both instances. The low melting point as well as the reactivity of the native metal compared to the oxide leads to plutonium oxides being a preferred form for applications such as nuclear fission reactor fuel (MOX-fuel). Alpha decay, the release of a high-energy helium nucleus, is the most common form of radioactive decay for plutonium. A 5 kg mass of 239Pu contains about 12.5×1024 atoms. With a half-life of 24,100 years, about 11.5×1012 of its atoms decay each second by emitting a 5.157 MeV alpha particle. This amounts to 9.68 watts of power. Heat produced by the deceleration of these alpha particles makes it warm to the touch.
By the late 20th century, new fields like genomics and proteomics were reversing this trend, with organismal biologists using molecular techniques, and molecular and cell biologists investigating the interplay between genes and the environment, as well as the genetics of natural populations of organisms.
=== Aromatic amines === In aromatic amines ("anilines"), nitrogen is often nearly planar owing to conjugation of the lone pair with the aryl substituent. The C-N distance is correspondingly shorter. In aniline, the C–N distance is the same as the C–C distances.
Sources: en.wikipedia.org
The Union's Senior Member (the university don that every society was required to have) resigned in protest at what he saw as Heseltine's profligacy, and was replaced by the young Maurice Shock. At the end of the Trinity (summer) Term 1954, Heseltine was elected President of the Oxford Union for Michaelmas term 1954, largely on the strength of his business management, and with the assistance of Union contemporaries Jeremy Isaacs and Anthony Howard, the then chairman and chairman-elect of the Oxford University Labour Club; Heseltine had even, for a brief period that term, joined a protest group against the Conservative government's testing of an H-Bomb. He had done little study at University, and passed his finals with the help of last-minute coaching from friends. After graduating with a second-class degree in Philosophy, politics and economics, described by his tutor Neville Ward-Perkins as "a great and undeserved triumph", he was permitted to stay on for an extra term to serve as Union President. The Union cellars were opened on 30 October 1954, and Heseltine persuaded the visiting Sir Bernard and Lady Docker to contribute to the considerable cost. Debates over which he presided included censorship of the Arts (no vote taken), welcoming the decline of British Imperialism (defeated 281–381) and calling for a "change in the principles and practice of British Trade Unions" (carried 358–200).
Hyperphosphorylation is believed to contribute to the development and progression of FTLD-tau, but evidence is inconclusive regarding the extent of its influence. There are significant differences in phosphorylation states across FTLD tauopathies, and the reasons for these differences are currently unknown. Pick bodies, for example, are not phosphorylated. Tau aggregation in FTLD-tau occurs not only through accumulation and altered phosphorylation but also through a disrupted balance between 3R and 4R isoforms.
Currently the Orbitrap analyzer exists in two variants: a standard trap and a compact high-field trap. In practical traps, the outer electrode is sustained at virtual ground and a voltage of 3.5 or 5 kV is applied to the inner electrode only. As a result, the resolving power at m/z 400 and 768 ms detection time can range from 60,000 for a standard trap at 3.5 kV to 280,000 for a high-field trap at 5 kV and with enhanced FT processing. Like in FTICR-MS the Orbitrap resolving power is proportional to the number of harmonic oscillations of the ions; as a result, the resolving power is inversely proportional to the square root of m/z and proportional to acquisition time. For example, the values above would double for m/z 100 and halve for m/z 1600. For the shortest transient of 96 ms these values would be reduced by 8 times, whereas a resolving power in excess of 1,000,000 has been demonstrated in 3-second transients. The Orbitrap analyzer can be interfaced to a linear ion trap (LTQ Orbitrap family of instruments), quadrupole mass filter (Q Exactive family) or directly to an ion source (Exactive instrument, all marketed by Thermo Fisher Scientific). In addition, a higher-energy collision cell can be appended to the C-trap, with the further addition of electron-transfer dissociation at its back. Most of these instruments have atmospheric pressure ion sources though an intermediate-pressure MALDI source can also be used (MALDI LTQ Orbitrap).
Wilkinson, who later wrote the book The Spirit Level, an economic historian from the University of Sussex who believed that societies with large differences in income would often cause less sense of togetherness; much data came from the longitudinal Whitehall Study at UCL; high-density lipoprotein (HDL) variation, found by Eric Brunner (epidemiologist) of UCL; Sir Richard Way; fibrinogen variation, found by Prof Sam Machin, haematologist at University College Hospital; Robert Sapolsky and his work with baboons in the Serengeti National Park showing HDL variation; how cortisol affected long-term health; atherosclerosis in Macacque monkeys and Carol Shiveley of Bowman Gray School of Medicine (since 2011 the Wake Forest School of Medicine) in North Carolina; health in Hungary since the Hungarian Revolution of 1956, and health of the UK during the Blitz; the Roseto effect found in Roseto, Pennsylvania by Stewart Wolf of the University of Oklahoma.
Pardaxin is a peptide produced by the Red Sea sole (P4, P5) and the Pacific Peacock sole (P1, P2, P3) that is used as a shark repellent. It causes lysis of mammalian and bacterial cells, similar to melittin.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.